This disclosure, in general, relates to energy delivery apparatuses, energy delivery systems, and methods for using same.
Laser interstitial thermal therapy (LITT) is a clinical tool for treating various malignant tumors in the liver, brain, ENT, or abdominal locations, as well as for treating benign alterations, such as prostate adenomas. Fiber optics that terminate in either bare fibers or diffusing applicators are punctured into the pathological volume to deliver the laser energy within the desired region of treatment. After positioning of the fibers, target tissues are irradiated causing volumetric heating that leads to thermal tissue necrosis. Tumor destruction with direct heating is therefore possible, while greatly limiting side effects or additional damage to surrounding structures. Furthermore, such thermal methods are associated with faster recovery than conventional surgical resection procedures.
Large applicators may cause trauma to healthy tissue when accessing the pathological volume. Applicators where light distribution results in high power density and heat generation, exceeding the thermal diffusion into the tissue can cause areas close to the applicator to char and potentially vaporize. Charring limits heat deposition within deeper tissue volumes due to increased absorption of light energy. As charred tissue continues to absorb incident light, its temperature continues to rise, leading to carbonization around the applicator. Further coagulation of deeper layers is dependent on heat conduction away from this carbonized volume.
While it is indeed possible to create large thermal lesions in this manner, the morphology of the resulting lesion is undesirable. Furthermore, high temperatures associated with the carbonized tissue often result in failure of the applicator tip and fiber optic with significant attendant risk for patients. As such, an applicator that limits charring and vaporization would be desirable.
Typical applicators are multi-component applicators. Procedures utilizing these applicators involve multiple insertion steps and time consuming actions taken by the medical professional performing the procedure. Such steps and actions prolong the surgical process and endanger the patient. In addition, multiple insertion steps potentially cause slippage of catheters and additional damage to surrounding tissue. As such, an improved applicator would be desirable.
This section provides a general summary of the disclosure, and is not a comprehensive disclosure of its full scope or all of its features.
An apparatus for delivering energy to a tissue having a housing that extends from a proximal end to a distal end and defines a lumen therein. An energy delivery component is positioned within the lumen. A first channel is formed adjacent to the energy delivery component. A second channel is formed adjacent to the housing. A first inlet is in communication with the first channel. A second outlet is in communication with the second channel. A fluid flow path enables a heat transfer fluid to flow from the first inlet to the first channel, along the second channel to the second outlet to transfer heat from the energy delivery component.
Further areas of applicability will become apparent from the description provided herein. The description and specific examples in this summary are intended for purposes of illustration only and are not intended to limit the scope of the present disclosure.
The drawings described herein are for illustrative purposes only of selected embodiments and not all possible implementations, and are not intended to limit the scope of the present disclosure.
Example embodiments will now be described more fully with reference to the accompanying drawings.
Energy delivery systems, such as Cooled Laser Fiber (CLF) systems, may be used to treat tissue within a patient. For example, a CLF system may be used to treat diseased tissues such as malignant and benign tumors and adenomas. In one exemplary embodiment, an energy delivery apparatus is inserted into the tissue, laser energy is dispersed within the tissue, and as a result, thermal necrosis occurs. The CLF system may be utilized to facilitate thermal coagulation of tissue, and more particularly to treat solid cancerous tumors in soft tissue, such as human and animal tissue.
In the exemplary embodiment depicted, the energy delivery apparatus 1 includes a housing 12 attached to a coupling assembly 26. A structure 16 separates the lumen of housing 12 into two channels. A first channel 20 is formed between the structure 16 and the housing 12 and a second channel 18 is formed between the energy delivery component 2 and the structure 16. The channels 18 and 20 communicate near or proximate the distal end of the housing 12 to allow fluid to pass from one channel to the other. The channels 18 and 20 may be isolated proximate the coupling assembly to allow fluid to, for example, enter port 8, flow through channel 18, return through channel 20, and exit via the outlet port 10. However, in other embodiments, the fluid may flow in the opposite direction. In this manner, counter current cooling fluid flow cools the housing 12, the structure 16, the energy delivery component 2, and the surrounding tissue. In the above exemplary embodiment, the structure 16 is depicted as tubular and the channels 18 and 20 are depicted as annuluses or concentric flow paths. However, various shaped structures 16 or shaped housings 12 may be used to form channels. As such, the tube-like structures, 12 and 16, may have cross-sectional shapes such as stars, squares, triangles, ovals, circles, and other shapes.
In one exemplary embodiment, the energy delivery apparatus 1 and the energy delivery component 2 are integrated or assembled just prior to insertion into the tissue. In another exemplary embodiment, the energy delivery apparatus 1 and the energy delivery component 2 are integrated or assembled during manufacture prior to being delivered for use.
Referring to
In one particular embodiment, the inner diameter of the inner tubular structure 16 may range from 0.6 mm to 2.0 mm, such as between 0.9 mm and 1.1 mm. The outer diameter of the inner tubular structure 16 may range from 0.7 mm to 2.1 mm, such as between 1.0 mm to 1.2 mm. The inner diameter of the outer housing may range from 1.0 mm to 1.9 m, such as between 1.2 mm and 1.4 mm, and the outer diameter of the outer housing may range from 1.2 mm to 2.5 mm, such as between 1.3 mm and 1.6 mm or less than 1.5 mm. For example, in a preferred embodiment in which a 0.4 mm core diameter fiber optic is used as the energy delivery component, and which is further provided with a buffer jacket of 0.730 mm outer diameter (OD), the inner tubular structure 16 is preferably 1.09 mm ID and 1.17 mm OD, and the outer housing is preferably 1.37 mm ID and 1.57 mm OD. Prefabrication or integration permits smaller diameters, which cause less peripheral tissue damage and may be easier to guide through tissue.
The energy delivery component 2 disposed within the fluid inlet lumen includes one or more optical waveguides positioned to direct light through both the inner tubular structure 16 and outer housing 12. In a particular embodiment, the energy delivery component 2 may be movable relative to the energy delivery apparatus 1, for example, translating along the axis of the energy delivery apparatus 1. Energy emitted from a diffusing tip of the energy delivery component 2 may pass through transparent housing 12 and structure 16. More than one region of tissue located along the housing 12 may be treated by moving the energy delivery component 2.
In at least one embodiment, the distal end 3 of the energy delivery component 2 preferably consists of an optical waveguide terminated with a diffusing tip element 9, as illustrated in
A cross section of a distal portion of an energy delivery apparatus 1 is illustrated in
A cross section of an alternative embodiment of the energy delivery apparatus 1 is illustrated in
Referring to
Returning to
An embodiment of a heat transfer medium supply apparatus may be a circulation type medium supply apparatus or a non-circulation type medium supply apparatus. In a circulation type medium supply apparatus, heat transfer medium is supplied from a reservoir to the energy delivery apparatus 1 and back to the reservoir. In a non-circulation type medium supply apparatus, heat transfer medium is supplied from a supply reservoir to the energy delivery apparatus 1 and then to a separate return reservoir. An example of a non-circulation type medium apparatus system includes a syringe pump, wherein a body of a syringe is a supply reservoir. Benefits of the use of a syringe pump include ease of metering the heat transfer medium and reduced potential for contamination of heat transfer medium being supplied to the circulation chamber. Suitable syringe pumps are commercially available from New Era Pump Systems Corporation and from Harvard Apparatus Corporation.
During delivery of energy, a cooling medium is introduced into the energy delivery apparatus 1 such that it flows through the fluid inlet lumen 18 around and in contact with the energy delivery component 2. The cooling medium exits the fluid inlet lumen 18 at the distal end of the inner tubular structure 16 and enters the fluid outlet lumen 20 at the distal end of the outer housing 12. The cooling medium flows back through the energy delivery apparatus 1 and exits the fluid outlet lumen 20 at the proximal end of the outer housing 12. During this travel the cooling medium contacts the inner tubular structure 16, the energy delivery component 2 and the outer housing 12, thus cooling the inner tubular structure 16, the energy delivery component 2, the outer tubular housing 12, and tissue 46 in contact with the energy delivery apparatus 1. Accordingly, both the tissue under treatment and the energy delivery apparatus 1 are cooled, minimizing the possibility of damaging energy delivery component 2 and energy delivery apparatus 1, or overheating adjacent tissue. It should be appreciated that the direction of flow could be reversed with the inlet flow traveling between the outer housing 12 and inner tubular structure 16 and the outlet flow traveling through the lumen of the inner tubular structure 16. In either method of operation, both the energy delivery component 2, and tissue 46 in contact with energy delivery apparatus 1 will experience cooling.
The temperature or flow rate of the cooling medium may be controlled to provide a desired cooling of tissue or energy delivery component. It is contemplated herein that the cooling medium may flow in a continuous or in an intermittent manner. Modulating supply temperature or flow rate of the cooling medium allows for increased deposition of photon energy by reducing or eliminating damage of tissue in direct contact with energy delivery apparatus 1, thus leading to development of increased possible lesions sizes.
The heat transfer medium may be a cooling medium or a heating medium. Examples of the cooling medium include room temperature and chilled fluids including liquids and gases such as saline solution, water, air, nitrogen, carbon dioxide, alcohols, and other suitable substances. Suitable substances include fluids with a suitable heat capacity or that are transmissive to the wavelength of light emitted from the energy delivery component 2. In some embodiments, the fluid may also include sealants, coagulants, anti-coagulants, anesthetics, optical agents, radio-opaque agents, dyes, magnetic resonance agents, therapeutic drugs, and chemotherapy agents, among other treatment agents.
In one exemplary embodiment, a fluid containing an MRI contrast agent may be used during insertion of the energy delivery apparatus 1. The cooling fluid may be optionally changed during energy delivery or therapeutic agents may be added at appropriate times during treatment.
It is contemplated herein that before, during or after the delivery of energy, induced temperatures may be monitored using MRI-based thermometry. Accordingly, procedures may be conducted for facilitating estimation of thermal damage at the active area of the energy delivery apparatus 1 and furthermore for preventing overheating of energy delivery apparatus 1, or other tissues in its surrounding area.
Cooling tissue in accordance with embodiments of the disclosures made herein permits creation of larger thermal lesions in a safer manner. Cooling of the tissue in contact with energy delivery apparatus 1 limits such tissue from being charred or carbonized by overheating. By limiting the formation of carbonized tissue, forward propagation of photons by direct absorption is not impeded, thus allowing continued lesion growth from volumetric heating by deeper penetration of photons prior to absorption, as opposed to primarily conductive heating as in the case of carbonized tissue. Furthermore, there is a reduced potential for the energy delivery component 2 to overheat and cause damage or destruction of components comprising the energy delivery apparatus 1. Furthermore, cooling tissue near the interface of energy delivery apparatus, where power density or induced temperature is highest, means that energy may be deposited at a higher rate or in greater quantity without reaching undesirable temperature elevation in tissue.
In one exemplary embodiment, energy may be applied at a rate of 8 to 9 watts for a period of 3 to 5 minutes. Lesions of greater than 2 cm diameter may be created quickly in less than 1 minute of treatment, improving the likelihood and efficiency of complete treatment of cancerous lesions or other tissues. Cooling methods in accordance with the disclosures maintain energy delivery apparatuses, such as laser applicators, below threshold temperatures for thermal destruction and providing removal of surface heat, allowing deeper and longer lasting penetration of photons in treated tissue.
In one exemplary embodiment, a cooled laser applicator in accord with the disclosure was constructed to house a fiber optic energy delivery component having a diffusing tip, a 400.mu.m fiber optic core, and a 700.mu.m outer diameter and to allow circulation of room-temperature cooling fluid at a rate of approximately 15 mL/minute. The cooled laser applicator and internal fiber optic were used in conjunction with a 980 nm wavelength laser energy source to produce thermal lesions in volumes of beef myocardium. For comparison, an identical diffusing tip fiber optic laser applicator was also used without a cooling apparatus.
Using un-cooled diffusing tips, power levels of 6 and 7 W resulted in failure (burning) of the tip before the end of a 5-minute dose period. At 8 W, fiber failure was immediate. In contrast, no failures were observed using the cooled diffusing applicator at powers up to 10 W for up to 8 minutes. Further, while significant char resulted in two of the un-cooled lesions, only the largest water-cooled dose resulted in char formation, which was minimal and not in contact with the applicator. Lesion dimensions increased with dose, but for un-cooled fibers, did not increase with power due to premature tip failure. In the cooled case, lesion dimensions increased monotonically with dose.
While the above exemplary embodiments depict a cooling system and cooling medium, a heating system and heating medium may alternatively be used. In general, a heat transfer medium may be used as fluid transferred through the channels.
Particular embodiments of the integrated apparatus provide advantageous technical features. For example, use of an integrated apparatus permits construction of the apparatus with smaller cross-section components and thinner wall structures. In particular, such construction reduces damage tissue surrounding the treated area and permits improved energy transmission beyond that achievable by the state of the art.
Aspects of the disclosure are found in an integrated apparatus for delivering energy to a tissue. The integrated apparatus includes a housing having a distal end and a tubular structure located within the housing forming a first annulus between the tubular structure and the housing. The tubular structure is configured to accept an energy delivery component and is configured to form a second annulus between the tubular structure and the energy delivery component. The first annulus and the second annulus are configured to communicate with each other proximate to the distal end of the housing.
Further aspects of the disclosure are found in an integrated apparatus for delivering energy to a tissue. The integrated apparatus includes a housing having a distal end, a coupling assembly, and a tubular structure. The coupling assembly interfaces with the housing opposite the distal end. The coupling assembly includes a first fluid access port and a second fluid access port. The first fluid access port is associated with a first annulus and the second fluid access port is associated with a second annulus. The coupling assembly includes an opening for introducing an energy delivery component. The tubular structure is located within the housing, forming the first annulus between the tubular structure and the housing. The tubular structure is configured to form the second annulus between the tubular structure and the energy delivery component. The first annulus and the second annulus are configured to communicate with each other proximate to the distal end of the housing.
Additional aspects of the disclosure are found in an energy delivery system. The energy delivery system includes an energy source, a heat transfer fluid source and an integrated apparatus. The integrated apparatus includes a housing having a distal end and a tubular structure located within the housing forming a first annulus between the tubular structure and the housing. The tubular structure is configured to accept an energy delivery component and is configured to form a second annulus between the tubular structure and the energy delivery component. The first annulus and the second annulus are configured to communicate with each other proximate to the distal end of the housing.
Additional aspects of the disclosure are found in an integrated apparatus. The integrated apparatus includes a housing having a distal end having a penetrating portion. The housing is configured to accept a waveguide internal to the housing. The housing includes a first channel and a second channel internal to the housing. The first channel and the second channel are configured to communicate with each other proximate to the distal end and isolated from each other proximate to an end opposite the distal end.
Further aspects of the disclosure are found in an integrated apparatus for delivering energy to a tissue. The integrated apparatus includes a housing having an energy delivery end, a first channel portion located internal to the housing and configured to direct coolant flow toward the energy delivery end, and a second channel portion located internal to the housing and configured to direct coolant flow away from the energy delivery end.
Aspects of the disclosure are also found in a method of interstitial thermal therapy. The method includes receiving a heat transfer medium at an intake portion of an integrated energy delivery apparatus from a source external to the integrated energy delivery apparatus; providing the heat transfer medium from an output region of the integrated energy delivery apparatus to a destination external to the integrated energy delivery apparatus; and receiving energy at a proximal end of an energy delivery component. The energy delivery component has a distal end internal to the integrated energy delivery apparatus and terminates proximate to a distal end of the integrated energy delivery apparatus.
Further aspects of the disclosure are found in a method for delivering energy to a tissue. The method includes locating an integrated apparatus proximate to the tissue; providing transfer fluid via the first annulus and the second annulus to exchange heat with the energy delivery apparatus; and providing energy to the tissue via the energy delivery component. The integrated apparatus includes a housing having a distal end and a tubular structure located within the housing forming a first annulus between the tubular structure and the housing. The tubular structure is configured to accept an energy delivery component and is configured to form a second annulus between the tubular structure and the energy delivery component. The first annulus and the second annulus are configured to communicate with each other proximate to the distal end of the housing.
Additional aspects of the disclosure are found in a method of performing interstitial thermal therapy. The method includes inserting an integrated energy delivery apparatus into a tissue and delivering energy via an energy delivery component to the tissue. The integrated energy delivery apparatus includes a housing including a first fluid channel internal to the housing and a second fluid channel internal to the housing. The housing is configured to accept an energy delivery component internal to the housing.
Aspects of the disclosure are also found in a method of interstitial thermal therapy. The method includes assembling an integrated energy delivery apparatus and providing the integrated energy delivery apparatus for insertion into a tissue. The integrated energy delivery apparatus includes a housing including a first fluid channel internal to the housing and a second fluid channel internal to the housing. The housing is configured to accept an energy delivery component internal to the housing.
Further aspects of the disclosure are found in an energy delivery apparatus having an outside diameter less than 1.5 mm.
The above-disclosed subject matter is to be considered illustrative, and not restrictive, and the appended claims are intended to cover all such modifications, enhancements, and other embodiments that fall within the true scope of the present invention. Thus, to the maximum extent allowed by law, the scope of the present invention is to be determined by the broadest permissible interpretation of the following claims and their equivalents, and shall not be restricted or limited by the foregoing detailed description.
This application is a continuation of U.S. patent application Ser. No. 14/508,050 filed on Oct. 7, 2014, which is a continuation of U.S. patent application Ser. No. 13/493,699 filed on Jun. 11, 2012, now U.S. Pat. No. 8,851,080 issued on Oct. 7, 2014, which is a continuation of U.S. patent application Ser. No. 11/749,854 filed on May 17, 2007, now U.S. Pat. No. 8,211,095 issued on Jul. 3, 2012, which is a continuation-in-part of U.S. patent application Ser. No. 10/703,304 filed on Nov. 7, 2003, now U.S. Pat. No. 7,270,656 issued on Sep. 18, 2007. The entire disclosures of each of the above applications are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4140130 | Storm, III | Feb 1979 | A |
4362161 | Reimels et al. | Dec 1982 | A |
4466697 | Daniel | Aug 1984 | A |
4515165 | Carroll | May 1985 | A |
4554925 | Young | Nov 1985 | A |
4580561 | Williamson | Apr 1986 | A |
4585298 | Mori | Apr 1986 | A |
4608977 | Brown | Sep 1986 | A |
4633875 | Turner | Jan 1987 | A |
4638800 | Michel | Jan 1987 | A |
4660952 | Toyoda et al. | Apr 1987 | A |
4669467 | Willett et al. | Jun 1987 | A |
4693556 | McCaughan, Jr. | Sep 1987 | A |
4740047 | Abe et al. | Apr 1988 | A |
4785815 | Cohen | Nov 1988 | A |
4832024 | Boussignac et al. | May 1989 | A |
4852567 | Sinofsky | Aug 1989 | A |
4862887 | Weber et al. | Sep 1989 | A |
4923459 | Nambu | May 1990 | A |
4959063 | Kojima | Sep 1990 | A |
4960109 | Lele | Oct 1990 | A |
4986628 | Lozhenko et al. | Jan 1991 | A |
5042980 | Baker et al. | Aug 1991 | A |
5061265 | Abela et al. | Oct 1991 | A |
5074632 | Potter | Dec 1991 | A |
5116345 | Jewell et al. | May 1992 | A |
5151096 | Khoury | Sep 1992 | A |
5169396 | Dowlatshahi et al. | Dec 1992 | A |
5196005 | Doiron | Mar 1993 | A |
5207669 | Baker et al. | May 1993 | A |
5219346 | Wagnieres et al. | Jun 1993 | A |
5222953 | Dowlatshahi | Jun 1993 | A |
5246436 | Rowe | Sep 1993 | A |
5269777 | Doiron et al. | Dec 1993 | A |
5292320 | Brown et al. | Mar 1994 | A |
5303324 | Lundahl | Apr 1994 | A |
5307812 | Hardy et al. | May 1994 | A |
5312392 | Hofstetter et al. | May 1994 | A |
5323779 | Hardy et al. | Jun 1994 | A |
5327884 | Hardy et al. | Jul 1994 | A |
5330465 | Doiron et al. | Jul 1994 | A |
5337381 | Biswas et al. | Aug 1994 | A |
5342357 | Nardella | Aug 1994 | A |
5348552 | Nakajima et al. | Sep 1994 | A |
5363458 | Pan et al. | Nov 1994 | A |
5368031 | Cline et al. | Nov 1994 | A |
5373571 | Reid et al. | Dec 1994 | A |
5429635 | Purcell, Jr. et al. | Jul 1995 | A |
5431647 | Purcell, Jr. et al. | Jul 1995 | A |
5441497 | Narciso, Jr. | Aug 1995 | A |
5454807 | Lennox et al. | Oct 1995 | A |
5483961 | Kelly et al. | Jan 1996 | A |
5496308 | Brown et al. | Mar 1996 | A |
5496309 | Saadat et al. | Mar 1996 | A |
5501655 | Rolt et al. | Mar 1996 | A |
5520681 | Fuller et al. | May 1996 | A |
5530780 | Ohsawa | Jun 1996 | A |
5536265 | van den Bergh | Jul 1996 | A |
5545161 | Imran | Aug 1996 | A |
5607421 | Jeevanandam et al. | Mar 1997 | A |
5647361 | Damadian | Jul 1997 | A |
5651785 | Abela et al. | Jul 1997 | A |
5665095 | Jacobson | Sep 1997 | A |
5688263 | Hauptmann et al. | Nov 1997 | A |
5754717 | Esch | May 1998 | A |
5792100 | Shantha | Aug 1998 | A |
5800557 | Elhami et al. | Sep 1998 | A |
5807390 | Fuller et al. | Sep 1998 | A |
5823941 | Shaunnessey | Oct 1998 | A |
5824005 | Motamedi et al. | Oct 1998 | A |
5830196 | Hicks | Nov 1998 | A |
5843073 | Sinofsky | Dec 1998 | A |
5855577 | Murphy-Chutorian et al. | Jan 1999 | A |
5861020 | Schwarzmaier | Jan 1999 | A |
5871521 | Kaneda et al. | Feb 1999 | A |
5906606 | Chee et al. | May 1999 | A |
5908415 | Sinofsky | Jun 1999 | A |
5946441 | Esch | Aug 1999 | A |
5947959 | Sinofsky | Sep 1999 | A |
5978541 | Doiron et al. | Nov 1999 | A |
5997571 | Farr et al. | Dec 1999 | A |
6004315 | Dumont | Dec 1999 | A |
6039728 | Berlien | Mar 2000 | A |
6048359 | Biel | Apr 2000 | A |
6071302 | Sinofsky et al. | Jun 2000 | A |
6102905 | Baxter et al. | Aug 2000 | A |
6106514 | O'Donnell, Jr. | Aug 2000 | A |
6113593 | Tu et al. | Sep 2000 | A |
6128522 | Acker et al. | Oct 2000 | A |
6174308 | Goble et al. | Jan 2001 | B1 |
6212426 | Swanson | Apr 2001 | B1 |
6270492 | Sinofsky | Aug 2001 | B1 |
6283958 | Vogl | Sep 2001 | B1 |
6311084 | Cormack et al. | Oct 2001 | B1 |
6315776 | Edwards et al. | Nov 2001 | B1 |
6334315 | Kotliar | Jan 2002 | B1 |
6343174 | Neuberger | Jan 2002 | B1 |
6361530 | Mersch | Mar 2002 | B1 |
6381483 | Hareyama et al. | Apr 2002 | B1 |
6383179 | Neuberger | May 2002 | B1 |
6418252 | Maitland | Jul 2002 | B1 |
6418337 | Torchia et al. | Jul 2002 | B1 |
6503246 | Har-Shai et al. | Jan 2003 | B1 |
6506189 | Rittman, III et al. | Jan 2003 | B1 |
6542767 | McNichols et al. | Apr 2003 | B1 |
6554824 | Davenport et al. | Apr 2003 | B2 |
6575969 | Rittman, III | Jun 2003 | B1 |
6576163 | Mersch | Jun 2003 | B2 |
6579286 | Maki et al. | Jun 2003 | B1 |
6802838 | Loeb | Oct 2004 | B2 |
6996478 | Sunshine et al. | Feb 2006 | B2 |
7077842 | Cosman | Jul 2006 | B1 |
7171253 | Dowlatshahi | Jan 2007 | B2 |
7270656 | Gowda | Sep 2007 | B2 |
7274847 | Gowda et al. | Sep 2007 | B2 |
7344529 | Torchia et al. | Mar 2008 | B2 |
7412141 | Gowda et al. | Aug 2008 | B2 |
7609927 | Gowda et al. | Oct 2009 | B2 |
7699838 | Breen et al. | Apr 2010 | B2 |
7780679 | Bobo, Sr. et al. | Aug 2010 | B2 |
7871406 | Nields et al. | Jan 2011 | B2 |
7909817 | Griffin | Mar 2011 | B2 |
8211095 | Gowda et al. | Jul 2012 | B2 |
8394099 | Patwardhan | Mar 2013 | B2 |
8644907 | Hartmann et al. | Feb 2014 | B2 |
8851080 | Gowda et al. | Oct 2014 | B2 |
9339336 | Gowda et al. | May 2016 | B2 |
20020193800 | Kienzle et al. | Dec 2002 | A1 |
20050065515 | Jahng | Mar 2005 | A1 |
20050075649 | Bova et al. | Apr 2005 | A1 |
20050131399 | Loeb | Jun 2005 | A1 |
20060084867 | Tremblay et al. | Apr 2006 | A1 |
20060149280 | Harvie et al. | Jul 2006 | A1 |
20060184163 | Breen et al. | Aug 2006 | A1 |
20070232898 | Huynh et al. | Oct 2007 | A1 |
20070239150 | Zvuloni et al. | Oct 2007 | A1 |
20070239169 | Plaskos et al. | Oct 2007 | A1 |
20070249938 | Shields | Oct 2007 | A1 |
20080004481 | Bax et al. | Jan 2008 | A1 |
20080186314 | Tomasello et al. | Aug 2008 | A1 |
20080200798 | Eklund et al. | Aug 2008 | A1 |
20090198309 | Gowda et al. | Aug 2009 | A1 |
20090292279 | Bliweis et al. | Nov 2009 | A1 |
20110040172 | Carpentier et al. | Feb 2011 | A1 |
20120245573 | Gowda et al. | Sep 2012 | A1 |
20130053867 | Gowda et al. | Feb 2013 | A1 |
20130123598 | Jenkins et al. | May 2013 | A1 |
20130165937 | Patwardhan | Jun 2013 | A1 |
20140088575 | Loeb | Mar 2014 | A1 |
20150094698 | Gowda et al. | Apr 2015 | A1 |
20150257830 | Tyc et al. | Sep 2015 | A1 |
20160151639 | Scharf et al. | Jun 2016 | A1 |
Number | Date | Country |
---|---|---|
2548226 | May 2005 | CA |
103442631 | Dec 2013 | CN |
4137983 | Jun 1992 | DE |
0361762 | Apr 1990 | EP |
0995406 | Apr 2000 | EP |
1689464 | Aug 2006 | EP |
2285307 | Feb 2011 | EP |
2412403 | Feb 2012 | EP |
2000217835 | Aug 2000 | JP |
2001046523 | Feb 2001 | JP |
2009524469 | Jul 2009 | JP |
2011516184 | May 2011 | JP |
WO-8903665 | May 1989 | WO |
WO-9614880 | May 1996 | WO |
WO-9720515 | Jun 1997 | WO |
WO-9932184 | Jul 1999 | WO |
WO-99032184 | Jul 1999 | WO |
WO-9942044 | Aug 1999 | WO |
WO-99042044 | Aug 1999 | WO |
WO-01095822 | Dec 2001 | WO |
WO-2002000298 | Jan 2002 | WO |
WO-0218011 | Mar 2002 | WO |
WO-03065880 | Aug 2003 | WO |
WO-2005046753 | May 2005 | WO |
WO-2006055554 | May 2006 | WO |
WO-2006078677 | Jul 2006 | WO |
WO-07005830 | Jan 2007 | WO |
WO-07086056 | Aug 2007 | WO |
WO-07090288 | Aug 2007 | WO |
WO-2007086056 | Aug 2007 | WO |
WO-2007090288 | Aug 2007 | WO |
WO-2009060394 | May 2009 | WO |
2009-125002 | Oct 2009 | WO |
WO-2009124301 | Oct 2009 | WO |
Entry |
---|
U.S. Appl. No. 15/221,862, 2016-0256220, filed Jul. 28, 2016, Gowda. |
European Search Report dated Mar. 17, 2017 for EP Application No. 16197308.6. |
Kim “Materials for multifunctional balloon catheters with capabilities in cardiac electrophysiological mapping and ablation therapy” NMAT2971, 8 pages, 2011. |
Ninth New Collegiate Dictionary, Copyright 1988 by Merriam-Webster Inc., Springfield, MA, p. 768. |
U.S. Appl. No. 10/703,304, filed Nov. 7, 2003 entitled “Cooled Laser Fiber for Improved Thermal Therapy”. |
Zhou “Piezoelectric films for high frequency ultrasonic transducers in biomedical applications” Prog Mater Sci., 56(2): 139-174, Feb. 2011. |
U.S. Appl. No. 14/508,050, 2015-0094698, filed Apr. 2, 2015, Gowda. |
U.S. Appl. No. 15/221,862, filed Jul. 28, 2016, Gowda. |
Communication under Rule 71(3)EPC dated Jul. 7, 2016 for European Application No. 09725941.8-1666. |
European Search Report dated Jun. 30, 2017 for European Application No. 16197308.6. |
International Search Report and Written Opinion dated Jul. 7, 2017 in corresponding International Application No. PCT/US2017/029896. |
International Preliminary Report on Patentability dated Nov. 8, 2018 in corresponding/related International Application No. PCT/US2017/029896. |
Communication pursuant to Article 94(3) EPC dated Sep. 12, 2014 for European Application No. 09 726 951.8-1652. |
International Preliminary Report and Written Opinion dated May 10, 2010 for PCT/US2009/39568 claiming benefit of U.S. Appl. No. 61/042,199, filed Apr. 3, 2008. |
International Preliminary Report on Patentability with Written Opinion dated May 30, 2007 for PCT/US04/37244 claiming benefit of U.S. Appl. No. 10/703,304, filed Nov. 7, 2003. |
International Search Report and Written Opinion dated Jul. 16, 2009 for PCT/US2009/39568 claiming benefit of U.S. Appl. No. 61/042,199, filed Apr. 3, 2008. |
International Search Report with Written Opinion dated Apr. 10, 2007 for PCT/US04/37244 claiming benefit of U.S. Appl. No. 10/703,304, filed Nov. 7, 2003. |
Japenese Office Action dated Jun. 9, 2015 for JP Patent Application No. 2011-503237 (7 pages) with English translation. |
U.S. Appl. No. 10/208,222, filed Jul. 30, 2002 entitled “Cooled Tip Laser Catheter for Sensing and Ablation of Cardiac Arrhythmias.” |
Weber et al., “Laser versus Radiofrequency Catheter Ablation of Ventricular Myocardium in Dogs: A Comparative Test,” Cardiology, vol. 88, 1997, pp. 346-352. |
Welch et al., “Evaluation of Cooling Techniques for the Protection of the Epidermis During Nd: YAG Laser Irradiation of the Skin,” in Neodymium-YAG Laser in Medicine and Surgery, S.N. Joffe, Ed. New York: Elsevier, 1983, pp. 196-204. |
Office Action dated Apr. 29, 2020 in corresponding/related Chinese Application No. 201780038816.5. |
Number | Date | Country | |
---|---|---|---|
20160256220 A1 | Sep 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14508050 | Oct 2014 | US |
Child | 15155657 | US | |
Parent | 13493699 | Jun 2012 | US |
Child | 14508050 | US | |
Parent | 11749854 | May 2007 | US |
Child | 13493699 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10703304 | Nov 2003 | US |
Child | 11749854 | US |